FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
|Slideshows|March 19, 2018
PrEP May Increase STI Risk
Author(s)Veronica Hackethal, MD
PrEP can decrease risk of HIV transmission. It can also contribute to risky sexual behavior and STIs.
Advertisement
What effect does PrEP have on sexual behavior? This meta-analysis offers sobering insights.
Advertisement
Related to this article
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
The Shift From Off-Label Use to On-Label Agitation Therapy
5